[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.163.92.62. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
August 1932

QUININE DERIVATIVES AND SPECIFIC IMMUNE SERUM IN THE TREATMENT OF PNEUMOCOCCUS INFECTION

Author Affiliations

MINNEAPOLIS

From the Department of Medicine, University of Minnesota.

Arch Intern Med (Chic). 1932;50(2):276-282. doi:10.1001/archinte.1932.00150150108011
Abstract

From the replies returned by twenty-five prominent German clinicians in response to questionnaires,1 it is evident that specific treatment of lobar pneumonia with immune serum has not as yet been generally accepted. Even in this country, an inquiry revealed that many physicians still rely on quinine derivatives and do not employ specific immune serum in treating lobar pneumonia. In view of the reports of Cole,2 Cecil and Sutliff,3 Park, Bullowa and Rosenbluth4 and others, showing the beneficial effects of type I serum in treating type I infections in a large number of patients, it seems unfortunate that quinine is still being used to the exclusion of specific serotherapy.

Quinine was introduced in the treatment of pneumonia about fifty years ago, chiefly by Jürgenson and Aufrecht. A new compound, ethylhydrocupreine, was popularized by Morgenroth and his associates in 1911. Ethylhydrocupreine is more pneumococcicidal than quinine in vitro

First Page Preview View Large
First page PDF preview
First page PDF preview
×